Concord Medical Services (CCM)
NYSE:CCM
Want to see CCM full AI Analyst Report?
CCM Stock Chart & Stats
$4.80
-$0.04(-0.90%)
At close: 4:00 PM EST
$4.80
-$0.04(-0.90%)
Day’s Range― - ―
52-Week Range$3.18 - $10.77
Previous CloseN/A
Volume954.00
Average Volume (3M)25.64K
Market Cap
$21.32M
Enterprise Value$3.34B
Total Cash (Recent Filing)$177.39M
Total Debt (Recent Filing)$3.82B
Price to Earnings (P/E)―
Beta0.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,815,458
10 Day Avg. Volume72,657
30 Day Avg. Volume25,639
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00853
P/FCF Ratio-0.01
Enterprise Value/Market Cap156.77
Enterprise Value/Revenue9.14
Enterprise Value/Gross Profit-79.86
Enterprise Value/Ebitda-9.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA 25.9% revenue rebound in 2025 reflects recovering demand and improved utilization of clinical services. Sustained top-line recovery provides a structural lever to absorb fixed costs, supports scale economics over months, and underpins a path toward margin recovery if maintained.
Narrowing LossesThe material reduction in net loss year-over-year signals operational progress and better cost/revenue mix. Persistently narrowing losses reduce near-term financing pressure and, if trend continues, can transition the business toward break-even and self-funding over a multi-quarter horizon.
Capital Market AccessIssuing low‑coupon convertibles via the Hong Kong listed subsidiary enhances funding flexibility and ties the group to broader capital markets. Access to H‑share liquidity and convertible structures can ease refinancing needs and support investment or working capital without immediate equity dilution.
Bears Say
High LeverageSubstantial debt combined with negative equity creates a structurally weak capital structure that limits financial flexibility. Elevated leverage raises refinancing and covenant risks, increases interest burden, and constrains strategic options unless sustained profitability or capital relief arrives.
Negative Cash FlowPersistent negative operating and free cash flows mean the core operations are not self-sustaining. Continued cash burn requires repeated external financing, increasing dilution or leverage risk and making medium‑term investment and debt servicing dependent on capital markets access.
Recurring Operating LossesRepeated operating losses and volatile gross profit point to structural margin weakness—likely from pricing pressure or high costs. This undercuts sustainable EBITDA generation and limits the firm's ability to build retained earnings, making durable profitability uncertain without business model changes.
Concord Medical Services News
CCM FAQ
What was Concord Medical Services’s price range in the past 12 months?
Concord Medical Services lowest stock price was $3.18 and its highest was $10.77 in the past 12 months.
What is Concord Medical Services’s market cap?
Concord Medical Services’s market cap is $21.32M.
When is Concord Medical Services’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Concord Medical Services’s earnings last quarter?
Currently, no data Available
Is Concord Medical Services overvalued?
According to Wall Street analysts Concord Medical Services’s price is currently Overvalued.
Does Concord Medical Services pay dividends?
Concord Medical Services pays a Notavailable dividend of $0.99 which represents an annual dividend yield of N/A. See more information on Concord Medical Services dividends here
What is Concord Medical Services’s EPS estimate?
Concord Medical Services’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Medical Services have?
Concord Medical Services has 2,815,458 shares outstanding.
What happened to Concord Medical Services’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Concord Medical Services?
Currently, no hedge funds are holding shares in CCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Medical Services
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
American Shared Hospital Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―